Russia's EnteroMix and China's approval rumour: what's true, what isn't

Reports circulating in early May 2026 say China is preparing to approve Russia's cancer vaccine EnteroMix. The story is interesting enough to be worth getting right — and the public conversation around it is currently a tangle of three distinct Russian vaccine programmes, one unconfirmed regulatory decision from a Chinese agency that has not commented publicly, and a layer of viral social-media claims that independent fact-checkers (notably Snopes, in September 2025) rated False. Newsorga unpacks each piece.

Three different Russian cancer vaccines

Most of the confusion comes from media reports that lump three separate Russian programmes into one. They are not the same thing:

1. EnteroMix. An experimental oncolytic virotherapy developed by the National Medical Research Radiological Center (NMRRC) of the Russian Ministry of Health in collaboration with the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences. It is not an mRNA vaccine, despite widespread mislabelling. It is a mixture of four live, replication-competent enteroviruses administered intravenously — discussed in detail below.

2. The NMRRC / Gamaleya Center personalized mRNA cancer vaccine. A separate programme — also NMRRC-led, in collaboration with the Gamaleya National Research Center (the same institute that developed the Sputnik V COVID-19 vaccine). This is an mRNA-based platform, designed to be tailored to each patient's tumour genetic profile. Volunteers were recruited in February 2025, the first trial was scheduled to begin in September-October 2025 with melanoma patients, with lung-cancer patients planned as the second cohort.

3. The FMBA colorectal cancer vaccine. A third and different again programme, developed by the Federal Medical and Biological Agency (FMBA) under Veronika Skvortsova. This is the vaccine Skvortsova told the Russian state news agency TASS on September 6, 2025 was "ready for use" and awaiting official approval — specifically for colorectal cancer. This is also the announcement that triggered the viral "Russia has a 100% efficacy cancer cure" social-media wave that Snopes rated False on September 14, 2025.

The Snopes fact-check was explicit: claims that "Russia's mRNA cancer vaccine EnteroMix is ready for clinical use with 100% efficacy" combine three completely separate vaccines into one impossible sentence. EnteroMix is not mRNA. The mRNA vaccine is not called EnteroMix. The colorectal vaccine that's "ready for use" is neither of those.

What EnteroMix actually is

Per the NMRRC's own descriptions and the consolidated Wikipedia entry sourced to Russian developer publications and independent analytical reviews, EnteroMix is an oncolytic virotherapy — an experimental cancer-treatment class that uses live viruses which selectively infect and replicate inside malignant cells, killing them by direct lysis and prompting an anti-tumour immune response.

The platform's distinctive feature is that it combines four enteroviruses rather than the single-virus approach used by every other oncolytic-virus product currently in serious clinical development worldwide:

• Coxsackievirus A21 (CVA21) — uses ICAM-1 and CD55/DAF cellular receptors. The same receptor profile is used by the Western-developed oncolytic candidate V937, which has been in Phase I/II trials in the United States, United Kingdom and Australia.
• Echovirus 7 (ECHO-7) — the same general virus family as the historical Latvian oncolytic product Rigvir, whose registration was suspended in 2019 by the Latvian State Agency of Medicines over discrepancies between declared and measured viral content.
• Enterovirus B75 (EV-B75) — a less-studied member of the same phylogenetic cluster.
• PV-Russo — a modified Sabin polio vaccine strain with rhinovirus-derived internal ribosome entry site (IRES) modifications intended to attenuate neurovirulence. Conceptually related to Duke University's PVSRIPO, which has completed Phase I evaluation in US glioblastoma patients.

The treatment is administered intravenously. The proposed mechanism, per the NMRRC, combines (1) direct virus-mediated destruction of tumour cells, (2) release of tumour-associated antigens that activate the immune system, and (3) targeting of heterogeneous tumour populations because the four viruses use different cellular receptors.

What stage the trials are actually at

EnteroMix is in Phase I human clinical trials. Concretely:

• Trial start: patient recruitment began in December 2024; first dosing in June 2025.
• Trial size: 48 volunteers at a single Russian center.
• Patient population: adults with advanced solid tumours for whom standard treatment options are no longer available. (This eligibility criterion is standard for first-in-human oncology trials, and is critically important context — these are patients out of conventional options, not a representative cancer population.)
• Trial design: open-label, single-centre, dose escalation. Primary objective is safety and tolerability. Secondary objectives include pharmacokinetics and exploratory response markers.
• Scheduled completion: October 2026.
• Phase II and Phase III have not begun. Phase II would test therapeutic efficacy in a larger population. Phase III, the standard for regulatory approval, would compare against existing standard of care in randomised trials.

The widely-circulated "60-80% tumour size reduction" and "100% efficacy" figures come from preclinical studies in animal models, not human trials. Preclinical efficacy in oncology is routinely strong and routinely fails to translate to humans — historic translation rates for oncology drug candidates from successful Phase I to FDA approval sit in the 5-10% range.

What's missing from the public record

An independent analytical review published on Zenodo on November 30, 2025 flagged several specific gaps that international regulators (the US Food and Drug Administration and the European Medicines Agency) would typically require before approving a replication-competent oncolytic virus product:

• No peer-reviewed publications in international scientific journals describing the development history, preclinical methodology, manufacturing process or clinical results of EnteroMix.
• No listing in ClinicalTrials.gov or other major international clinical-trial registries — a standard expectation for any product seeking eventual cross-border regulatory consideration.
• No full nucleotide genome sequences of the four viral strains used in EnteroMix in open scientific databases. This is particularly significant for the PV-Russo poliovirus-derivative component, because the WHO's Global Polio Eradication Initiative requires full sequence disclosure for any genetically modified construct derived from vaccine poliovirus strains.
• No published viral-shedding or biodistribution data for the multivirus formulation — relevant because patients receiving live replication-competent viruses can shed them and potentially expose contacts.
• No published assessment of inter-viral recombination risk when multiple replication-competent enteroviruses from different species (Enterovirus B and Enterovirus C) are administered concurrently.

Newsorga's read on the data gap: none of this proves EnteroMix does not work. It does mean that, by the evidentiary standards major non-Russian regulators apply, EnteroMix is not currently in a position to be approved by any agency outside Russia — including China's National Medical Products Administration.

What 'China approving' actually means here

The May 2026 reports — most prominently from The Daily CPEC, Pakistan Observer and a small cluster of trade outlets including Global Brands Magazine — say China is "considering" or "may approve" EnteroMix. Newsorga's reading after checking the primary sources:

• China's National Medical Products Administration (NMPA) has issued no public statement about EnteroMix.
• No bilateral Russia-China agreement specifically covering EnteroMix approval has been publicly disclosed by either government.
• The reporting traces back to Russian institutional statements about "interest from international partners" and broader Russia-China health-cooperation framing — not to a concrete NMPA review docket or regulatory milestone.

This is not to say it cannot happen. China does have routes to approve foreign therapeutics on the basis of overseas Phase I data when those treatments target conditions with high unmet need — particularly under the NMPA's 2017 reforms that introduced expedited review for rare-disease and innovative-therapy products. And Russia-China healthcare cooperation has accelerated through 2024-2026, partly as a function of broader geopolitical alignment. The point is that the news, as reported, is anticipatory rather than confirmed.

What the claims do and do not support

Sorting the public claims about EnteroMix by how well they hold up against the actual evidence:

Claims that are accurate.

• EnteroMix is a real, ongoing Russian experimental cancer-treatment programme.
• Phase I trials are under way at the NMRRC in Russia.
• Preclinical animal trials reportedly showed meaningful tumour reduction.
• Russia intends to offer the treatment free of charge to Russian patients if it is eventually approved.

Claims that are misleading or false.

• "EnteroMix is an mRNA vaccine." False. EnteroMix is an oncolytic virotherapy. The separate NMRRC/Gamaleya mRNA programme is what gets confused with it.
• "100% efficacy in trials." Misleading. The 100% figure refers to immune response activation in preclinical animal studies. It is not a cancer-cure metric and not a Phase III result.
• "Ready for clinical use." Conflates the FMBA colorectal vaccine (which Skvortsova said in September 2025 is ready) with EnteroMix (which is still in Phase I).
• "China has approved." False as of May 2026. China is reported to be considering. There is no NMPA approval.
• "Russia has a working cancer vaccine." Substantially overstated. Russia has multiple cancer-vaccine programmes at various stages, including a colorectal-cancer vaccine that is reported by domestic officials to be near approval. None of them have completed Phase III trials. None have peer-reviewed efficacy data published internationally.

Why this matters beyond Russia

Three reasons this story is genuinely consequential, regardless of the EnteroMix-specific approval question:

1. Oncolytic virotherapy is a legitimate scientific direction. Multiple Western programmes — CVA21/V937, PVSRIPO, T-VEC (Amgen's approved oncolytic herpes virus for melanoma) — are showing real, if incremental, clinical benefit. EnteroMix is in the same broad category as those, and the multi-virus combination approach is at least conceptually interesting even if its execution remains unverified.

2. Personalised cancer vaccines (the mRNA programme) are a global race. Russia's NMRRC/Gamaleya mRNA work runs in parallel with Moderna's mRNA-4157 melanoma vaccine programme, BioNTech's personalised mRNA platforms, and the UK NHS's newly-launched cancer vaccine launch pad. The fact that Russia is in this race at all is the substantive scientific story, not the social-media-virality story.

3. China's regulatory openness signals geopolitics, not just clinical evidence. If the NMPA does eventually clear EnteroMix on the basis of Russian Phase I data — without independent Western trial validation — it will say more about Russia-China geopolitical alignment than about the underlying science. Watching the regulatory pathway is therefore a useful indicator of where NMPA policy is heading on Russian therapeutics generally in a sanctions-fragmented global pharmaceutical economy.

What to watch through 2026

Newsorga is tracking four data points:

1. NMPA public docket. Whether China's drug regulator actually publishes a notice of evaluation, conditional-approval framework or rejection on EnteroMix. Until that happens, the "China is approving" framing remains aspirational.

2. The October 2026 Phase I completion. The scheduled end date of the 48-patient Russian trial. Safety and tolerability data from that read-out will be the first clean piece of human evidence — and whether it is published in a peer-reviewed international journal or only in Russian-language outlets will tell you a lot about whether the developers are seeking international scientific legitimacy.

3. Phase II initiation. Whether Russia moves directly to Phase II in 2027 with a larger patient population testing actual therapeutic efficacy, and whether any non-Russian sites are included.

4. Genome-sequence publication. Whether the NMRRC publishes the full nucleotide sequences of the four viral strains in open databases. This is the single most-tractable transparency step the developers could take to begin meeting international biosafety expectations, and the fact that they have not yet done so is the cleanest signal that EnteroMix is, for now, a Russia-only therapeutic story.

Bottom line. Russia has a real, ongoing EnteroMix cancer-treatment programme. It is an oncolytic virotherapy, not an mRNA vaccine. It is in Phase I human trials. The dramatic "100% efficacy" and "ready for use" claims that drove most international coverage came from conflating EnteroMix with two separate Russian cancer-vaccine programmes. China has not approved it. China may consider it. Newsorga will follow the NMPA docket, the October 2026 trial read-out, and whether genome sequences are published as the next concrete data points.